Comparative Pharmacology
Head-to-head clinical analysis: ONSOLIS versus TALWIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ONSOLIS versus TALWIN.
ONSOLIS vs TALWIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Onsolis (fentanyl buccal soluble film) is an opioid agonist that binds to mu-opioid receptors in the central nervous system, producing analgesia by increasing potassium conductance and inhibiting calcium channels, leading to reduced neurotransmitter release and hyperpolarization of neurons.
Agonist at kappa-opioid receptors and antagonist at mu-opioid receptors; produces analgesia through spinal and supraspinal mechanisms.
Onsolis (fentanyl buccal soluble film) is indicated for breakthrough pain in opioid-tolerant patients. The initial dose is 200 mcg placed on the buccal mucosa; titrate to effective dose in 200 mcg increments across subsequent episodes. Maximum frequency: 4 doses per day. Allow at least 2 hours between doses.
50 mg orally every 3-4 hours as needed; maximum 600 mg/day. For severe pain, 30 mg intramuscularly or subcutaneously every 3-4 hours; maximum 360 mg/day parenterally.
None Documented
None Documented
Terminal elimination half-life is approximately 3-5 hours in adults, providing sustained analgesic effect with multiple daily dosing.
2-3 hours in adults; prolonged to 4-6 hours in hepatic impairment; clinical context: short half-life necessitates frequent dosing for chronic pain
Primarily hepatic metabolism via glucuronidation, with approximately 70% of the dose excreted in urine as metabolites and 10-15% in feces as unchanged drug.
Renal: 60-70% as unchanged drug and metabolites (pentazocine and its glucuronide conjugate); biliary/fecal: 20-30%
Category C
Category C
Opioid Analgesic
Opioid Analgesic